PKD1P1 and neoplasm: We observed the more potent antitumor efficacy of H2Mab-250-hG1 in relation to both the tumor volume (p < 0.01, Figure 6A) and weight (p < 0.01, Figure 6B) compared with that of trastuzumab at day 29 (Figure 6C).